Logo

Fosun Pharma Signs an Agreement with BioNTech to Develop and Commercialize BNT162 for COVID-19

Share this

Fosun Pharma Signs an Agreement with BioNTech to Develop and Commercialize BNT162 for COVID-19

Shots:

  • BioNTech to receive $135M as up front- future investment & milestone payments and $50M as an equity investment for 1-580-777 ordinary shares in BioNTech. Fosun to get the rights to commercialize BNT162 in China while BioNTech retain all rights of the vaccine in ROW
  • The companies will jointly conduct clinical studies of BNT162 in China- leveraging BioNTech’s mRNA vaccine technology and Fosun’s clinical development and commercialization capabilities in China
  • The companies will share profits from sales in China. Additionally- BioNtech with its partner Polymun will supply the mRNA vaccine for clinical studies from GMP manufacturing facilities in the EU

Click here ­to­ read full press release/ article | Ref: Business wire | Image: Businesswire


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions